

Inge M Van Oort

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6224778/publications.pdf>

Version: 2024-02-01

170
papers

8,544
citations

70961

41
h-index

46693

89
g-index

172
all docs

172
docs citations

172
times ranked

10997
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 142-150.	2.0	5
2	Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 133-141.	2.0	2
3	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	2.0	19
4	Clinical implementation of preâ€biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. <i>BJU International</i> , 2022, 129, 480-490.	1.3	5
5	The effect of chemotherapy on the exposureâ€response relation of abiraterone in metastatic castrationâ€resistant prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1170-1178.	1.1	5
6	Adjustment disorder in cancer patients after treatment: prevalence and acceptance of psychological treatment. <i>Supportive Care in Cancer</i> , 2022, 30, 1797-1806.	1.0	6
7	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	0.9	3
8	Dissemination of the European Association of Urology Guidelines Through Social Media: Strategy, Results, and Future Developments. <i>European Urology Focus</i> , 2022, 8, 1541-1544.	1.6	3
9	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-40.	0.8	0
10	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4
11	The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Careâ€”A Systematic Review. <i>Cancers</i> , 2022, 14, 1059.	1.7	30
12	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. <i>Drugs - Real World Outcomes</i> , 2022, , 1.	0.7	0
13	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	2.9	5
14	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
15	An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	0.7	2
16	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5051-5051.	0.8	2
17	Editorâ€™ summary: A paradigm shift in castration-resistant prostate cancer management. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 601-603.	2.0	3
18	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolmmunology</i> , 2022, 11, .	2.1	3

#	ARTICLE	IF	CITATIONS
19	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	2.6	6
20	A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines. <i>European Urology Focus</i> , 2021, 7, 1195-1204.	1.6	18
21	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	1.6	1
22	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	2.0	37
23	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.	2.3	28
24	Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based Study. <i>European Urology Focus</i> , 2021, 7, 332-339.	1.6	6
25	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRM) and metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 93-93.	0.8	9
26	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 871-879.	2.0	8
27	Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3325-3334.	3.3	15
28	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	3.2	53
29	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	2.1	9
30	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1110-1119.	2.0	40
31	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5047-5047.	0.8	1
32	Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity. , 2021, , .		0
33	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. <i>Journal of Palliative Medicine</i> , 2021, 24, 1789-1797.	0.6	4
34	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	5.1	159
35	A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. <i>European Urology</i> , 2021, 80, 442-449.	0.9	31
36	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e7-729.e16.	0.8	34

#	ARTICLE	IF	CITATIONS
37	Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. <i>Eur Urol</i> 2021;80:442-9. <i>European Urology</i> , 2021, 80, e101.	0.9	4
38	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	0.7	13
39	Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 771956.	1.3	5
40	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	1.7	5
41	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. <i>European Urology Oncology</i> , 2020, 3, 455-463.	2.6	17
42	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. <i>European Urology Oncology</i> , 2020, 3, 231-238.	2.6	30
43	Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy. <i>Health Informatics Journal</i> , 2020, 26, 1194-1207.	1.1	9
44	Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative. <i>Journal of Cancer Education</i> , 2020, 35, 1141-1148.	0.6	7
45	⁶⁸ Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 147-154.	0.9	8
46	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.	0.9	4
47	Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e17-735.e25.	0.8	19
48	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	1.3	4
49	Histopathological re-evaluations of biopsies in prostate cancer: a nationwide observational study. <i>Scandinavian Journal of Urology</i> , 2020, 54, 463-469.	0.6	3
50	Lutetium-177-PSMA- ¹⁷⁷ Lu as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	1.1	32
51	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 3756.	1.7	4
52	Optimizing psychosocial support in prostate cancer patients during active surveillance. <i>International Journal of Urological Nursing</i> , 2020, 14, 115-123.	0.1	4
53	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	1.5	25
54	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. <i>Future Oncology</i> , 2020, 16, 1371-1384.	1.1	25

#	ARTICLE	IF	CITATIONS
55	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	1.5	18
56	⁶⁸ Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1607-1614.	2.8	11
57	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	1.3	41
58	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 753-760.	1.1	5
59	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
60	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5566-5566.	0.8	15
61	Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.. <i>Journal of Clinical Oncology</i> , 2020, 38, 121-121.	0.8	3
62	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
63	Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1374-1385.	1.5	6
64	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
65	A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1179-1185.	1.1	9
66	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e946-e956.	0.9	5
67	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. <i>European Urology</i> , 2019, 76, 574-581.	0.9	114
68	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. <i>Nature Communications</i> , 2019, 10, 5251.	5.8	130
69	Nationwide treatment patterns and survival of older patients with prostate cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 252-258.	0.5	19
70	Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 79-87.	0.9	18
71	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. <i>European Urology</i> , 2019, 75, 570-578.	0.9	521
72	Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 337-343.	2.0	3

#	ARTICLE	IF	CITATIONS
73	The Combination of Enzalutamide and Opioids: A Painful Pitfall?. <i>European Urology</i> , 2019, 75, 351-352.	0.9	7
74	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	1.6	23
75	Does a food intervention makes abiraterone treatment affordable?. <i>Journal of Clinical Oncology</i> , 2019, 37, e16523-e16523.	0.8	0
76	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 336-342.	1.2	41
77	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 222-229.	1.0	11
78	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e223-e231.	0.9	27
79	Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 122-129.	1.1	41
80	223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases. <i>Clinical Nuclear Medicine</i> , 2018, 43, 9-16.	0.7	18
81	Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, e6-e8.	0.6	7
82	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5036-5036.	0.8	2
83	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 219-219.	0.8	2
84	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 248-248.	0.8	5
85	Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 344-344.	0.8	11
86	Novel use of Twitter to disseminate and evaluate adherence to clinical guidelines by the European Association of Urology. <i>BJU International</i> , 2017, 119, 820-822.	1.3	28
87	Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. <i>BJU International</i> , 2017, 120, 659-665.	1.3	45
88	Fear of cancer recurrence: a significant concern among partners of prostate cancer survivors. <i>Psycho-Oncology</i> , 2017, 26, 2079-2085.	1.0	33
89	Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 12-19.	2.0	102
90	A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. <i>Prostate</i> , 2017, 77, 1401-1407.	1.2	61

#	ARTICLE	IF	CITATIONS
91	PD47-05 ELDERLY PROSTATE CANCER PATIENTS HAVE A WORSE PROGNOSIS THAN YOUNGER PATIENTS: A POPULATION-BASED STUDY IN THE NETHERLANDS.. Journal of Urology, 2017, 197, .	0.2	0
92	MP33-17 POTENTIAL ROLE OF A NOVEL URINARY BIOMARKER-BASED RISK SCORE TO SELECT PATIENTS FOR MULTIPARAMETRIC MRI FOR PROSTATE CANCER DETECTION.. Journal of Urology, 2017, 197, .	0.2	0
93	MP02-02 MULTICENTER VALIDATION STUDY OF A MOLECULAR URINE TEST TO PREDICT HIGH-GRADE PROSTATE CANCER.. Journal of Urology, 2016, 195, .	0.2	0
94	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clinical Pharmacokinetics, 2016, 55, 1369-1380.	1.6	74
95	Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. European Urology, 2016, 70, 740-748.	0.9	292
96	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. Oncology, 2016, 91, 267-273.	0.9	10
97	Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial. Health Expectations, 2016, 19, 459-470.	1.1	39
98	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. Prostate, 2016, 76, 32-40.	1.2	13
99	The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited. Prostate, 2016, 76, 897-904.	1.2	8
100	PREDICT: model for prediction of survival in localized prostate cancer. World Journal of Urology, 2016, 34, 789-795.	1.2	10
101	MP63-14 THE IMPACT OF A MINIMUM CYSTECTOMY VOLUME POLICY ON THE CENTRALIZATION AND QUALITY OF BLADDER CANCER CARE IN THE NETHERLANDS. Journal of Urology, 2016, 195, .	0.2	0
102	Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clinical Chemistry and Laboratory Medicine, 2016, 54, 483-492.	1.4	47
103	Fear of cancer recurrence in prostate cancer survivors. Acta Oncologica, 2016, 55, 821-827.	0.8	61
104	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. Journal of Clinical Oncology, 2016, 34, 330-330.	0.8	1
105	Elevated HOXC6/DLX1 mRNA biomarker levels in urine to help select patients at increased risk for high-grade prostate cancer detection upon prostate biopsy.. Journal of Clinical Oncology, 2016, 34, 31-31.	0.8	1
106	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. Journal of Clinical Oncology, 2016, 34, 329-329.	0.8	0
107	Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clinical Cancer Research, 2015, 21, 3061-3070.	3.2	193
108	Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary" prostate cancer. Prostate, 2015, 75, 474-483.	1.2	12

#	ARTICLE	IF	CITATIONS
109	The oncologic role of local treatment in primary metastatic prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 755-761.	1.2	14
110	Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e1-71.e9.	0.8	62
111	CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. <i>International Journal of Cancer</i> , 2015, 136, E760-72.	2.3	34
112	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e1-265.e7.	0.8	14
113	Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. <i>BJU International</i> , 2015, 115, 571-579.	1.3	29
114	Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling. <i>Archivos Espanoles De Urologia</i> , 2015, 68, 296-306.	0.1	5
115	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. <i>Cancer</i> , 2014, 120, 968-975.	2.0	121
116	Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonance-Guided Biopsy for Early Risk Restratification in Active Surveillance of Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2014, 49, 165-172.	3.5	83
117	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. <i>European Journal of Cancer</i> , 2014, 50, 1090-1099.	1.3	88
118	Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes. <i>Journal of Urology</i> , 2014, 191, 1132-1138.	0.2	95
119	Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer. <i>European Urology</i> , 2014, 65, 534-542.	0.9	306
120	Self-reported acne is not associated with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 941-945.	0.8	3
121	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014, 74, 1222-1230.	1.2	28
122	Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. <i>Therapeutic Advances in Urology</i> , 2014, 6, 245-252.	0.9	14
123	PD14-10 CURRENT TRENDS IN MANAGEMENT OF HIGH-RISK PROSTATE CANCER IN EUROPE: RESULTS OF A WEB-BASED SURVEY BY THE PROSTATE CANCER WORKING GROUP OF THE YOUNG ACADEMIC UROLOGISTS WORKING PARTY OF THE EUROPEAN ASSOCIATION OF UROLOGY. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
124	Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 109-109.	0.8	0
125	Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. <i>Journal of Clinical Oncology</i> , 2014, 32, 242-242.	0.8	1
126	The Predictive Value of Endorectal 3 Tesla Multiparametric Magnetic Resonance Imaging for Extraprostatic Extension in Patients with Low, Intermediate and High Risk Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 1728-1734.	0.2	177

#	ARTICLE	IF	CITATIONS
127	Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. <i>BJU International</i> , 2013, 111, 564-573.	1.3	61
128	Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 238-250.e1.	0.9	26
129	Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. <i>International Journal of Molecular Sciences</i> , 2013, 14, 11347-11355.	1.8	25
130	Quality of life after prostate cancer treatments in patients comparable at baseline. <i>British Journal of Cancer</i> , 2013, 108, 1784-1789.	2.9	56
131	Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2013, 48, 152-157.	3.5	63
132	Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5055-5055.	0.8	1
133	Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score $\geq 3 + 3 = 6$ Upon Schematic TRUS-Guided Biopsy. <i>Investigative Radiology</i> , 2012, 47, 153-158.	3.5	65
134	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012, 44, 1326-1329.	9.4	178
135	Value of PET/CT and MR Lymphography in Treatment of Prostate Cancer Patients With Lymph Node Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 712-718.	0.4	45
136	2104 PROSPECTIVE MULTICENTER EVALUATION OF PCA3 AND TMPRSS2-ERG GENE FUSIONS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.2	2
137	Urologists'™ and GPs'™ knowledge of hereditary prostate cancer is suboptimal for prostate cancer counseling: a nation-wide survey in The Netherlands. <i>Familial Cancer</i> , 2012, 11, 195-200.	0.9	6
138	Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging-Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort. <i>European Urology</i> , 2012, 61, 177-184.	0.9	277
139	Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy. <i>World Journal of Urology</i> , 2012, 30, 105-110.	1.2	18
140	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 172-172.	0.8	1
141	Value of multimodality MRI and MR-guided biopsy at inclusion in an active surveillance protocol for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 105-105.	0.8	0
142	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15112-e15112.	0.8	0
143	Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging. <i>Radiology</i> , 2011, 261, 46-66.	3.6	618
144	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011, 43, 1098-1103.	9.4	251

#	ARTICLE	IF	CITATIONS
145	1907 CORRELATION OF PCA3 AND MRI WITH BIOPSY OUTCOME. Journal of Urology, 2011, 185, .	0.2	0
146	Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy. Histopathology, 2011, 59, 692-702.	1.6	18
147	Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. Radiology, 2011, 259, 453-461.	3.6	537
148	Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis. Journal of Clinical Oncology, 2011, 29, 4510-4515.	0.8	72
149	Feasibility of 3T Dynamic Contrast-Enhanced Magnetic Resonance-Guided Biopsy in Localizing Local Recurrence of Prostate Cancer After External Beam Radiation Therapy. Investigative Radiology, 2010, 45, 121-125.	3.5	56
150	The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy. Histopathology, 2010, 56, 464-471.	1.6	49
151	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. Science Translational Medicine, 2010, 2, 62ra92.	5.8	140
152	Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. European Journal of Cancer, 2010, 46, 3294-3299.	1.3	31
153	Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative Biopsies and Increased Prostate Specific Antigen. Journal of Urology, 2010, 183, 520-528.	0.2	344
154	Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nature Genetics, 2009, 41, 1122-1126.	9.4	313
155	Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU International, 2009, 104, 321-325.	1.3	23
156	A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant". Urologic Oncology: Seminars and Original Investigations, 2009, 27, 509-513.	0.8	15
157	VALUE OF 3 TESLA MULTI-MODALITY DIRECTED MR GUIDED BIOPSY TO DETECT PROSTATE CANCER IN PATIENTS AFTER AT LEAST TWO PREVIOUS NEGATIVE BIOPSIES AND ELEVATED PSA. Journal of Urology, 2009, 181, 706.	0.2	2
158	Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer. World Journal of Urology, 2008, 26, 237-241.	1.2	26
159	The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system. BJU International, 2008, 102, 438-441.	1.3	23
160	Prognostic Factors in Radical Prostatectomy Specimens: What Do We Need to Know from Pathologists?. European Urology Supplements, 2008, 7, 715-722.	0.1	1
161	THE CORRELATION BETWEEN THE LENGTH OF POSITIVE SURGICAL MARGINS AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal of Urology, 2008, 179, 196-196.	0.2	1
162	POSITIVE MARGINS AFTER RADICAL PROSTATECTOMY, DOES NUMBER OF MARGINS AND SITE MATTER?. Journal of Urology, 2008, 179, 197-198.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Thirty-Two-Channel Coil 3T Magnetic Resonance-Guided Biopsies of Prostate Tumor Suspicious Regions Identified on Multimodality 3T Magnetic Resonance Imaging: Technique and Feasibility. Investigative Radiology, 2008, 43, 686-694.	3.5	104
164	The prognostic value of E-cadherin and the cadherin-associated molecules β -catenin and p120 ^{cas} in prostate cancer specific survival: A long-term follow-up study. Prostate, 2007, 67, 1432-1438.	1.2	54
165	468: Prognostic Significance of Number of Tumors in T2C Prostate Cancer. Journal of Urology, 2007, 177, 157-157.	0.2	0
166	331: The 2002 TNM Subclassification of Unilateral PT2 Prostate Cancer is not Relevant. Journal of Urology, 2007, 177, 112-112.	0.2	0
167	1877: Are Small-Volume Prostate Cancers Insignificant?. Journal of Urology, 2007, 177, 623-624.	0.2	0
168	1156: Maximal Tumor Diameter is not a Prognostic Factor for Biochemical Recurrence in Patients with Prostate Cancer. Journal of Urology, 2007, 177, 381-382.	0.2	0
169	Does the Tertiary Gleason Pattern Influence the PSA Progression-Free Interval after Retropubic Radical Prostatectomy for Organ-Confined Prostate Cancer?. European Urology, 2005, 48, 572-576.	0.9	47
170	DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer. European Urology, 2003, 44, 8-16.	0.9	603